Abstract
The purpose of this study was to determine the factors that pharmaceutical industry representatives believe are important in the drug benefit decisions of MCOs. Respondents indicated that a drug's clinical features and acquisition cost were the most important factors in making drug-coverage decisions. Ninety percent of respondents indicated that they provide some type of pharmacoeconomic data on either some or almost every visit with their customers. Twenty (95%) of 21 respondents thought that current pharmacoeconomic information was helpful to MCOs in making drug benefit decisions. However, 80% thought important barriers existed to using health outcome and pharmacoeconomic data.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 39-45 |
| Number of pages | 7 |
| Journal | Drug Benefit Trends |
| Volume | 13 |
| Issue number | 3 |
| State | Published - 2001 |
| Externally published | Yes |
Keywords
- MCOs
- Pharmaceutical industry
- Pharmacoeconomics
ASJC Scopus subject areas
- Health Policy
- Pharmacology (medical)